Sponsors

Randox set to release eight new Quality Controls

Randox offers an extensive product offering comprising third-party quality controls and calibrators, interlaboratory data management, external quality assessment, calibration verification and molecular IQC and EQA for infectious disease testing. Randox Quality Control is now set to add eight Quality Controls to its range.

With approximately 70% of clinical decisions based on laboratory test results, it is essential that the results provided are accurate and reliable to prevent potential misdiagnosis or inappropriate treatment.

The new products are:

Active Vitamin B12 Control – The Acusera Active B12 Control is designed to deliver a cost-effective, high-quality solution for use in the quantitative determination of Active Vitamin B12 in human serum and plasma.

Anti-Mullerian Hormone (AMH) Control – The Randox Acusera AMH control is designed to use as a third-party control for the quantitative determination of Anti-Mullerian Hormone (AMH).

Brain Natriuretic Peptide (BNP) Control – Providing a true third-party solution, the new Acusera BNP Control is designed for use with in vitro diagnostics assays for the quantitative determination of BNP in human serum and plasma. The BNP control delivers an unbiased, independent assessment of analytical performance, helping to ensure accurate and reliable patient testing for BNP.

Bone Markers (Serum) Control – The lyophilised Serum Bone Marker Control is intended for use with in vitro diagnostic assays for the quantitative determination of Procollagen Type 1 N-Terminal Propeptide (P1NP), Osteocalcin (OC) and Bone Alkaline Phosphatase (B-ALP) in serum samples. This lyophilised Serum Bone Marker Control is assayed with target value and is suitable for use on automated analysers.

Pre-Eclampsia Control – The Pre-Eclampsia Control is intended for use with in vitro diagnostic assays for the quantitative determination of placental growth factor (PIGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in human serum and plasma. The Pre-Eclampsia Control is assayed with target values and is suitable for use on various immunoassay analysers.

Serum Indices Control – Intended for IVD use to monitor an instrument’s response to, and ability to detect haemolysed, icteric or lipaemia samples which can impact patient test results. The Acusera Serum Indices Control is qualitatively ranked and reported as -, =, == for Haemolysis, Icterus, and Lipaemia.

Xanthochromia Control – Randox Acusera Xanthochromia Quality Control is designed to deliver a cost-effective, high-quality solution for use in monitoring the performance of bilirubin and oxyhaemoglobin in cerebrospinal fluid (CSF) using a spectrophotometer.

(PSA) Ultra Low Control: This is intended for use with in vitro diagnostic assays for the quantitative determination of low levels of prostate-specific antigen (PSA) in human serum and plasma. This control delivers a true-third party solution for use in monitoring the performance. The PSA Ultra Low Control is assayed with target values and is suitable for use on various analysers, and for use of trained laboratory professionals and can be used in determining the precision of testing systems and in identifying sources of variation.

 

Latest Issues

The Power to Disrupt - Clinical Diagnostics Expo UK

15 Hatfields
16 September, 2024

Microbe Conference 2024

Crowne Plaza Hotel, Sheffield, UK
20-22 September, 2024

Cardiac Marker Dialogues: Cardiac Biomarkers in Real Time – Experiences and Opportunities

Hilton Glasgow, 1 William Street, Glasgow, Scotland, G3 8HT
26-27 September, 2024

The British Association for Cytopathology Annual Scientific Meeting

Aztec Hotel and Spa, Bristol, BS32 4TS
18 October, 2024

UK NEQAS: Navigating Quality Standards in Point of Care Testing

The Hyatt Regency Hotel, Birmingham, UK
23 October, 2024